Stomach cancer patients have good chemotherapy results, but are being pushed to death by “innovative drugs”? At a time when mRNA cancer vaccines are showing significant benefits, CAR-T, which is currently another popular anti-cancer technology, has fallen into a “high-risk moment.” Recently, Ms. Cheng revealed to reporters a medical death. Her husband Zhan had stomach cancer. After being treated at Shanghai Changhai Hospital, his condition stabilized. However, on the recommendation of the attending physician, Zhan joined Yimufeng Biotechnology Co., Ltd. in a CAR-T cell clinical trial called IMC002. Regrettably, just a few hours after the test drug was injected, he had a sudden bilateral subdural hematoma and cerebral hernia. He was forced to undergo a craniotomy, and eventually died more than a month later. Although Yi Mufeng stated in a response sent to reporters, “We have cooperated with the ethical evaluation and the investigation according to law, and compensation is based on the determination of legal responsibility, and no prior judgment has been made.” However, at the critical window of CAR-T transition from hematoma to solid tumors, the death of a case of “chemotherapy was fine, the return occurred on the day” was not just a doctor-patient dispute, but a sample of the CAR-T transfusion safety chain for solid tumors. In response, Yi Mufeng Biotech replied to Blue Whale News: “Regarding the determination of responsibility for the incident, the relevant facts should be fairly clarified under legal procedures. Our company will fully cooperate with the investigation and evaluation work carried out by all parties in accordance with the law, respect the formal conclusions drawn from independent investigations and evaluations, and do not make preliminary judgments.”

Stomach cancer patients have good chemotherapy results, but are being pushed to death by “innovative drugs”? At a time when mRNA cancer vaccines are showing significant benefits, CAR-T, which is currently another popular anti-cancer technology, has fallen into a “high-risk moment.” Recently, Ms. Cheng revealed to reporters a medical death. Her husband Zhan had stomach cancer. After being treated at Shanghai Changhai Hospital, his condition stabilized. However, on the recommendation of the attending physician, Zhan joined Yimufeng Biotechnology Co., Ltd. in a CAR-T cell clinical trial called IMC002. Regrettably, just a few hours after the test drug was injected, he had a sudden bilateral subdural hematoma and cerebral hernia. He was forced to undergo a craniotomy, and eventually died more than a month later. Although Yi Mufeng stated in a response sent to reporters, “We have cooperated with the ethical evaluation and the investigation according to law, and compensation is based on the determination of legal responsibility, and no prior judgment has been made.” However, at the critical window of CAR-T transition from hematoma to solid tumors, the death of a case of “chemotherapy was fine, the return occurred on the day” was not just a doctor-patient dispute, but a sample of the CAR-T transfusion safety chain for solid tumors. In response, Yi Mufeng Biotech replied to Blue Whale News: “Regarding the determination of responsibility for the incident, the relevant facts should be fairly clarified under legal procedures. Our company will fully cooperate with the investigation and evaluation work carried out by all parties in accordance with the law, respect the formal conclusions drawn from independent investigations and evaluations, and do not make preliminary judgments.”